Search
Displaying 171–180 of 526 for “Retinitis pigmentosa”
-
Foundation News
With nearly two decades of leadership in vision and neuroscience research and a committed tenure with the Foundation, Dr. Laster will spearhead the Foundation’s scientific strategy in her new role.
-
RD Fund Invests in Perceive Pharma for Development of Neuroprotective Therapies
Research NewsPerceive Pharma is a spin out of Perceive Biotherapeutics.
-
Foundation Fighting Blindness Celebrates 20 Years of VisionWalk
Foundation NewsVisionWalk has been uniting communities across the country for 20 years, all while raising awareness and funding research driving treatments and cures for blinding diseases.
-
VISIONS 2026: United in Vision
The United in Vision 2026 conference unites two prestigious events—the Foundation Fighting Blindness VISIONS conference and the Retinal International World Congress—into one extraordinary global gathering. Scheduled from Wednesday, June 10, to Saturday, June 13, 2026, at the Omni Fort Worth Hotel and Fort Worth Convention Center in Fort Worth, Texas.
-
Research News
The company is also planning to conduct the clinical trial at sites in the EU.
-
Foundation News
ARPA-H award establishes multi-disciplinary consortium of industry experts to address current limitations and advance innovative technologies for vision-restoring whole eye transplantation.
Goal to bring light to those who are blind through first-ever successful vision recovery in six whole eye transplants in humans by 2030.
-
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
Research NewsThe Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Research NewsMerger will provide additional capital for gene therapy development.
